20 June 2013
Keywords: abbott, enanta, begin, ph, hcv, trial, usa
Article | 23 February 2009
The USA's Abbott Laboratories and Enanta Pharmaceuticals have begun a first-in-human study evaluating ABT-450, an oral protease inhibitor for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 February 2009
19 June 2013
© 2013 thepharmaletter.com